.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,730,706

« Back to Dashboard

Details for Patent: 6,730,706

Title: Treatments using venlafaxine
Abstract:This invention provides a method of treating obesity, generalized anxiety disorder, post-traumatic stress disorder, late luteal phase dysphoric disorder (premenstrual syndrome), attention deficit disorder, with and without hyperactivity, Gilles de la Tourette syndrome, bulimia nervosa or Shy Drager Syndrome in a mammal by administering to the mammal an effective amount of a hydroxycycloalkanephenethyl amine of the following structural formula: ##STR1## in which A is a moiety of the formula ##STR2## where the dotted line represents optional unsaturation; R.sub.1 is hydrogen or alkyl; R.sub.2 is alkyl; R.sub.4 is hydrogen, alkyl, formyl, or alkanol; R.sub.5 and R.sub.6 are, independently, hydrogen, hydroxyl, alkyl, alkoxy, alkanoyloxy, cyano, nitro, alkylmercapto, amino, alkylamino, dialkylamino, alkanamido, halo, trifluoromethyl, or taken together, methylene dioxy; R.sub.7 is hydrogen or alkyl; and n is 0, 1, 2, 3, or 4; or a pharmaceutically acceptable salt thereof.
Inventor(s): Rudolph; Richard L. (Berwyn, PA), Upton; G. Virginia (Radnor, PA)
Assignee: Wyeth (Madison, NJ)
Filing Date:Mar 25, 2003
Application Number:10/396,043
Claims:1. A method of treating late luteal phase dysphoric disorder in a mammal, comprising administering to the mammal an effective amount of a compound of the formula: ##STR6##

in which A is a moiety of the formula ##STR7##

wherein the dotted line represents optional unsaturation; R.sub.1 is hydrogen or alkyl of 1 to 6 carbon atoms; R.sub.2 is alkyl of 1 to 6 carbon atoms; R.sub.4 is hydrogen, alkyl of 1 to 6 carbon atoms, formyl, or alkanol of 2 to 7 carbon atoms; R.sub.5 and R.sub.6 are, independently, hydrogen, hydroxyl, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, alkanoyloxy of 2 to 7 carbon atoms, cyano, nitro, alkylmercapto of 1 to 6 carbon atoms, amino, alkylamino of 1 to 6 carbon atoms, dialkylamino in which each alkyl group is of 1 to 6 carbon atoms, alkanamido of 2 to 7 carbon atoms, halo, trifluoromethyl, or taken together, methylene dioxy; R.sub.7 is hydrogen or alkyl of 1 to 6 carbon atoms; and n is 0, 1, 2, 3, or 4;

or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 wherein the mammal is a human.

3. The method of claim 1 wherein the composition is administered orally.

4. A method of treating late luteal phase dysphoric disorder in a mammal, comprising administering to the mammal a pharmaceutical composition comprising an effective amount of a compound of the formula: ##STR8##

in which A is a moiety of the formula ##STR9##

wherein the dotted line represents optional unsaturation, and R.sub.1 is hydrogen or alkyl of 1 to 6 carbon atoms; R.sub.2 is alkyl of 1 to 6 carbon atoms; R.sub.4 is hydrogen, alkyl of 1 to 6 carbon atoms, formyl, or alkanol of 2 to 7 carbon atoms; R.sub.5 and R.sub.6 are, independently, hydrogen, hydroxyl, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, alkanoyloxy of 2 to 7 carbon atoms, cyano, nitro, alkylmercapto of 1 to 6 carbon atoms, amino, alkylamino of 1 to 6 carbon atoms, dialkylamino in which each alkyl group is of 1 to 6 carbon atoms, alkanamido of 2 to 7 carbon atoms, halo, trifluoromethyl, or taken together, methylene dioxy; R.sub.7 is hydrogen or alkyl of 1 to 6 carbon atoms; and n is 0, 1, 2, 3, or 4;

or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

5. The method of claim 4 wherein the compound is: ##STR10##

in which A is a moiety of the formula ##STR11##

wherein the dotted line represents optional unsaturation, and R.sub.1 is hydrogen or alkyl of 1 to 3 carbon atoms; R.sub.2 is alkyl of 1 to 3 carbon atoms; R.sub.5 is hydrogen, hydroxyl, alkoxy of 1 to 3 carbon atoms, chloro, bromo, trifluoromethyl or alkyl of 1 to 3 carbon atoms; R.sub.6 is alkyl of 1 to 3 carbon atoms, alkoxy of 1 to 3 carbon atoms, chloro, bromo, trifluoromethyl or alkanoyloxy of 2 to 3 carbon atoms; R.sub.7 is hydrogen or alkyl of 1 to 3 carbon atoms;

or a pharmaceutically acceptable salt thereof.

6. The method of claim 1 wherein R.sub.5 and R.sub.6 are both in the meta positions or one of R.sub.5 or R.sub.6 is in the para position and n is 2.

7. The method of claim 1 wherein the compound is 1-[(2-dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol or a pharmaceutically acceptable salt thereof.

8. The method of claim 1 wherein the compound is 1-[2-(dimethylamino)-1-(4-hydroxyphenyl)ethyl]cyclohexanol or a pharmaceutically acceptable salt thereof.

9. The method of claim 1 wherein the effective amount comprises a daily dose of between about 50 mg/day and about 375 mg/day.

10. The method of claim 1 wherein the effective amount comprises a daily dose of between about 75 mg/day and about 200 mg/day.

11. The method of claim 1 wherein the mammal is a human.

12. The method of claim 1 wherein the pharmaceutical composition is administered orally.

13. The method of claim 1 wherein the pharmaceutical composition is in a unit dosage form which is a tablet.

14. The method of claim 1 wherein the pharmaceutical composition is in a unit dosage form which is a capsule.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc